Skip to main content

Drug Interactions between orlistat and triheptanoin

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Major

orlistat triheptanoin

Applies to: orlistat and triheptanoin

GENERALLY AVOID: Coadministration of triheptanoin, a medium-chain triglyceride, with a pancreatic lipase inhibitor, such as orlistat, may reduce the systemic exposure of heptanoate, the active metabolite of triheptanoin, and diminish the therapeutic effects of triheptanoin. The primary function of pancreatic lipase inhibitors is to decrease gastrointestinal absorption of fats. Lipase inhibitors bind to lipase enzymes in the intestine and prevent the hydrolysis of dietary triglycerides into monoglycerides and fatty acids which results in a reduction in the absorption of dietary fat.

MANAGEMENT: Coadministration of triheptanoin with a pancreatic lipase inhibitor, such as orlistat, should be avoided.

References

  1. "Product Information. Dojolvi (triheptanoin)." Ultragenyx Pharmaceutical (2020):

Switch to consumer interaction data

Drug and food interactions

No alcohol/food interactions were found. However, this does not necessarily mean no interactions exist. Always consult your healthcare provider.

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.


Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.